Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims match the provided VELCADE (bortezomib) label excerpts (indications). However, the patient assistance and manufacturing/marketed-generic availability claims are not addressed in the supplied prescribing information, so they are unsupported by the provided label content.
Category Scores
Accurate Statements
Velcade is a medication used to treat multiple myeloma.
Supported by INDICATIONS AND USAGE 1.1: VELCADE is indicated for treatment of adult patients with multiple myeloma.
Velcade is a medication used to treat mantle cell lymphoma.
Supported by INDICATIONS AND USAGE 1.2: VELCADE is indicated for treatment of adult patients with mantle cell lymphoma.
Unsupported Statements
Takeda Pharmaceuticals offers patient assistance programs for eligible patients to help afford Velcade.
Not supported by any provided label excerpt (sections provided do not discuss patient assistance programs).
Takeda Pharmaceuticals patient assistance programs may include co-pay assistance for commercially insured patients.
Not supported by any provided label excerpt.
Takeda Pharmaceuticals patient assistance programs may include medication at no cost for uninsured or underinsured individuals who meet specific criteria.
Not supported by any provided label excerpt.
Velcade is manufactured by Takeda Pharmaceuticals.
Not supported by any provided label excerpt (manufacturing/label owner/manufacturer statements not included in provided sections).
Generic versions of bortezomib have become available in some markets following patent expirations.
Not supported by any provided label excerpt (no information on generic availability or patent status in provided sections).
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
Unsupported claims relate to patient assistance/manufacturing/generic availability rather than to prescribing, administration, contraindications, or safety-critical risks in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several non-prescribing claims (patient assistance, manufacturer, generic availability) are not supported by the supplied FDA-approved label excerpts.
Suggested Improvement
Limit statements to label-supported content from the provided excerpts (e.g., indications) and remove/verify patient assistance/manufacturer/generic availability claims against appropriate, label-relevant sources.